Insulinoma Mimic: Tramadol-induced Hypoglycemia. [PDF]
O'Hara S +5 more
europepmc +1 more source
Revisiting the heterogeneity of maturity-onset diabetes of the young: A new classification scheme based on pathogenic mechanisms. [PDF]
Shi P +6 more
europepmc +1 more source
Synergism of Synthetic Sulfonamides and Natural Antioxidants for the Management of Diabetes Mellitus Associated with Oxidative Stress. [PDF]
Dinu Iacob A +5 more
europepmc +1 more source
Changes in β-Cell Function and Insulin Sensitivity During Treatment With Dapagliflozin Alone or in Combination With Exenatide in Type 2 Diabetes. [PDF]
Triplitt C +8 more
europepmc +1 more source
Effects of GLP-1 receptor agonists on body weight and cardiovascular outcomes: a review. [PDF]
van Maren SJF +5 more
europepmc +1 more source
Effect of oral semaglutide on cardiometabolic risk factors in overweight and obese individuals with or without diabetes: a systematic review and meta-analysis. [PDF]
Seighali N +12 more
europepmc +1 more source
Maternal diabetes subtypes and offspring cutaneous health: developmental programming of sebaceous gland function in over 330,000 live births. [PDF]
Honig E +4 more
europepmc +1 more source
Pharmaceutical agents targeting K<sub>ATP</sub> channel modulate sweet taste sensitivity in mice. [PDF]
Sawai C +6 more
europepmc +1 more source
Related searches:
Characterization and Significance of Sulfonylurea Receptors
Diabetes Care, 1990This study describes and characterizes a putative sulfonylurea receptor. The radioligand used was [3H]glipizide (9 Ci/mmol). The β-cell plasma membranes were derived from a transplantable rat insulinoma generated by subcutaneous injection of RINm5F cells and purified by ultracentrifugation on a 15–55% sucrose gradient. Specific binding of [3H]glipizide
Harold E Lebovitz +2 more
exaly +3 more sources
A New Mesangial Triumvirate: Sulfonylureas, Their Receptors and Endosulfines
Although sulfonylureas have long been therapeutically utilized for their hypoglycemic properties in type 2 diabetic patients, there is a paucity of clinical or experimental data that suggests that this pharmacotherapeutic class confers a benefit on the course of diabetic renal disease.
Jerry, Yee, Balàzs, Szamosfalvi
core +4 more sources

